GOLDEN SUN SECURITIES·2026-03-08 12:04Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical sector [5] Core Insights - The pharmaceutical sector has experienced a decline of 2.78% this week, ranking 17th out of 31 sectors, with a year-to-date increase of 0.1%, ranking 24th out of 31 [9] - The 2026 government work report emphasizes the importance of the biopharmaceutical industry, positioning it as a key pillar for economic growth and industrial upgrading, particularly highlighting the innovative drug sector as a core beneficiary [10][11] - The inclusion of brain-computer interfaces in the government work report marks a significant policy shift, elevating the field to a national industrial support framework, which is expected to enhance market focus on related technologies [11] Company Dynamics - China Biopharmaceutical has entered an exclusive licensing agreement with Sanofi for the innovative drug Roflumilast, with potential payments totaling up to $1.53 billion, including an upfront payment of $135 million [12] - Deking Pharmaceuticals has reached a global exclusive licensing agreement with UCB for ATG-201, with an upfront payment of $80 million and potential milestone payments totaling approximately $1.1 billion [13] - East China Pharmaceutical has received approval to conduct clinical trials for DR30206, a targeted therapy for non-small cell lung cancer [14] - Yahui Pharmaceutical has obtained approval for APL-1702, a product aimed at treating cervical intraepithelial neoplasia [15] Suggested Focus Areas - The report suggests focusing on the innovative drug supply chain and the brain-computer interface sector as key investment opportunities [4][16]